Key Takeaway: 4D Molecular Therapeutics announced that its inhalable gene therapy for cystic fibrosis demonstrated early positive signs of improved quality of life in a small patient group. This development could represent a significant advancement in the treatment of cystic fibrosis. Further details on the study and its implications are anticipated.
Price reaction · baseline $14.98 (2023-09-19 close) · hit pre-market · 1 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
-3.2%
Market Sentiment Analysis
POSITIVE FACTORS
Inhalable gene therapy shows early positive signs.
Improved quality of life reported in patients.
Potential breakthrough for cystic fibrosis treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Nicole DeFeudis
Senior Reporter
4D Molecular Therapeutics announced Wednesday that its inhalable gene therapy for cystic fibrosis showed signs of improved quality of life in an early look from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Frequently Asked Questions
What is the focus of 4DMT's recent announcement?
4DMT announced early positive signs for its inhalable gene therapy for cystic fibrosis.
How did patients respond to the therapy?
Patients reported improved quality of life from the inhalable gene therapy.